Boehringer In­gel­heim ex­tends 2020 col­lab with Ox­ford Bio­Ther­a­peu­tics; Eu­ro­pean biotechs claim pos­i­tive PhI I/O da­ta

Ox­ford Bio­Ther­a­peu­tics said Thurs­day that it has ex­tend­ed its sec­ond col­lab­o­ra­tion with Boehringer In­gel­heim for an­oth­er two years. The biotech said that the ex­ten­sion will add more pro­grams to al­low for de­vel­op­ing “nov­el can­cer im­munother­a­pies” in in­di­ca­tions with a high­er un­met need.

The San Jose, CA-based biotech has been a part­ner with the pri­vate Ger­man phar­ma since 2013, when the com­pa­nies first inked an on­col­o­gy deal us­ing Ox­ford’s dis­cov­ery plat­form, called OGAP. The sec­ond deal was con­firmed in 2020 to dis­cov­er ad­di­tion­al se­lec­tive tar­gets for “strate­gic can­cer in­di­ca­tions,” again with Boehringer us­ing Ox­ford’s OGAP plat­form and com­bined with Boehringer’s T-cell en­gager, can­cer vac­cine and on­colyt­ic virus plat­forms.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER